Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianfeng Luo

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Molecular Carcinogenesis|May 11, 2011
Urinary polyphenols, glutathione S-transferases copy number variation, and breast cancer risk: results from the Shanghai women's health studyJianfeng Luo, Yu-Tang Gao, Wong-Ho Chow, et al.
Nature Communications|July 12, 2022
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerBiyun Wang, Tao Sun, Yannan Zhao, et al.
Stroke and Vascular Neurology|September 25, 2020
Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 monthsYi Sui, Jianfeng Luo, Chunyao Dong, et al.
Iscience|April 20, 2026
Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primaryShuangyue Pan, Jinyan Wang, Jing Liu, et al.
Therapeutic Advances in Medical Oncology|January 24, 2022
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trialXiaowei Zhang, Ran Duan, Yusheng Wang, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of AgingQianhua Zhao, Rosebud O Roberts, Ding Ding, et al.
Frontiers in Neurorobotics|June 1, 2022
Safety and Feasibility of a Novel Exoskeleton for Locomotor Rehabilitation of Subjects With Spinal Cord Injury: A Prospective, Multi-Center, and Cross-Over Clinical TrialSijing Chen, Zhanbin Wang, Yongqiang Li, et al.
The Lancet. Oncology|July 28, 2024
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trialXin Liu, Xiaowei Zhang, Shiyu Jiang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2025
A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in ChinaFeng Sun, Yang Li, Yilin Zhang, et al.
Lancet (London, England)|June 15, 2023
6-month consequences of COVID-19 in patients discharged from hospital: a cohort studyChaolin Huang, Lixue Huang, Yeming Wang, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Molecular Carcinogenesis|May 11, 2011
Urinary polyphenols, glutathione S-transferases copy number variation, and breast cancer risk: results from the Shanghai women's health studyJianfeng Luo, Yu-Tang Gao, Wong-Ho Chow, et al.
Nature Communications|July 12, 2022
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerBiyun Wang, Tao Sun, Yannan Zhao, et al.
Stroke and Vascular Neurology|September 25, 2020
Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 monthsYi Sui, Jianfeng Luo, Chunyao Dong, et al.
Iscience|April 20, 2026
Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primaryShuangyue Pan, Jinyan Wang, Jing Liu, et al.
Therapeutic Advances in Medical Oncology|January 24, 2022
FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trialXiaowei Zhang, Ran Duan, Yusheng Wang, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of AgingQianhua Zhao, Rosebud O Roberts, Ding Ding, et al.
Frontiers in Neurorobotics|June 1, 2022
Safety and Feasibility of a Novel Exoskeleton for Locomotor Rehabilitation of Subjects With Spinal Cord Injury: A Prospective, Multi-Center, and Cross-Over Clinical TrialSijing Chen, Zhanbin Wang, Yongqiang Li, et al.
The Lancet. Oncology|July 28, 2024
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trialXin Liu, Xiaowei Zhang, Shiyu Jiang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2025
A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in ChinaFeng Sun, Yang Li, Yilin Zhang, et al.
Lancet (London, England)|June 15, 2023
6-month consequences of COVID-19 in patients discharged from hospital: a cohort studyChaolin Huang, Lixue Huang, Yeming Wang, et al.
Pageof 17